The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade.
 
Elshad Hasanov
Honoraria - Targeted Oncology
Consulting or Advisory Role - Pfizer; Telix Pharmaceuticals
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - American Association for Cancer Research; AstraZeneca; Aveo; Axess Oncology; Bayer; Eisai; EMD Serono; Exelixis; IDEOlogy Health; Janssen Oncology; Medscape; Merck; Millennium Medical Publishing; Myovant Sciences; Nektar; Novartis; OncLive; Pfizer; Propella Therapeutics; Sanofi; Seagen; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Novartis; Pfizer; Physicans' Education Resource; Propella Therapeutics; RevHealth; Sanofi; Xcures
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Novartis; Pfizer
 
Brian I. Rini
Leadership - MashupMD; MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - Alkermes; Aravive; Arrowhead Pharmaceuticals; Athenex; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Debiopharm Group; Eisai; EUSA Pharma; Genentech; HiberCell; Merck; NiKang Therapeutics; Pfizer; Surface Oncology
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Dracen (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Pionyr (Inst); Point Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Stata (Inst); Surface Oncology (Inst); Vasgene Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Katy Beckermann
Consulting or Advisory Role - Alpine Immune Sciences; Aravive; AstraZeneca; AVEO; Bristol-Myers Squibb; Exelixis; Merck; Sanofi; Seagen
Research Funding - Aravive (Inst); ArsenalBio (Inst); Bristol-Myers Squibb; Merck Sharp & Dohme; Pionyr (Inst)
 
Joshua David Palmer
Honoraria - American Society for Radiation Oncology; Novocure; Varian Medical Systems
Consulting or Advisory Role - Huron Consulting; More Health
Research Funding - Kroger; Varian Medical Systems
Travel, Accommodations, Expenses - American Society for Radiation Oncology; Novocure
 
Amir Mortazavi
Honoraria - Motive Medical Intelligence
Consulting or Advisory Role - Debiopharm Group; Pfizer; Seagen
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
 
Roserika Brooks
No Relationships to Disclose
 
Travis Solley
No Relationships to Disclose
 
Lauren Michelle Wood
No Relationships to Disclose
 
Naomi B. Haas
Consulting or Advisory Role - AVEO; Calithera Biosciences; Eisai; Exelixis; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Expert Testimony - Lilly (I)
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; AVEO; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; Sanofi; Synthekine; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Merck Serono; Pfizer; Sanofi/Aventis
Speakers' Bureau - Bayer; Exelixis; Pfizer
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Eric Jonasch
Consulting or Advisory Role - Aveo; Eisai; Exelixis; Ipsen; Merck; NiKang Therapeutics; Novartis
Research Funding - Arrowhead Pharmaceuticals (Inst); Aveo (Inst); Corvus Pharmaceuticals (Inst); Merck (Inst); NiKang Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer